Olmesartan, Oxidant Stress and in Vivo Re-Endothelialization Capacity of Endothelial Progenitor Cells from Patients with Chronic Kidney Disease (OECD Study) - OECD Study

niversity of the Saarland0 个研究点开始时间: 2009年2月11日最近更新: 2013年1月21日

试验速览

暂无简介。

•* Signed written informed consent
•* Woman or man aged 18 to 70 years
•* Chronic Kidney Disease (CKD II-IV)
•* Endogenous creatinine clearance between 15 ml/min and 90 ml/min. No impending need for dialysis during the study
•* HbA1C <8% for patients with diabetes mellitus type II
•* No Autosomal Dominant Polyzystic Kidney Disesase (ADPKD)
•* No known metabolic diease except diabetes mellitus type II
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

•* Myelodysplastic or –proliferative diseases
•* Malignant disease diagnosed within the last 5 years
•* Renal anemia (Hb =10,5 g/dl for men or =10 g/dl for women) or therapy with rHuEPO or analogs
•* Therapy with growth factors, e.g. GM-CSF or VEGF
•* Statin Therapy
•* Bleeding episodes relevant for Hb within the last 3 months or known gastrointestinal bleeding sources
•* Foreseeable need for dialysis
•* Sitting dBP >100 mmHg with standard antihypertensives (incl. ACE Inhibitors or ARB)
•* Sitting sBP >100 mmHg with standard antihypertensives (incl. ACE Inhibitors or ARB)
•* Known intolerance of ARBs, e.g. Olmetec®, Diovan®, Lorzaar®, Atacand®, Aprovel®, Mircardis®, Teveten®
•* Known HIV infection
•* Systemic chemotherapy or radiotherapy
•* Chronic infection and/or CRP >10 mg/l at the beginning of the study
•* Acute cardiovascular episodes
•* Organ transplants
•* Pregnant or lactating woman
•* Woman of childbearing potential without adequate contraception
•* Psychiatric disease or chronic cerebral attacks
•* Non-compliance or participation in another clinical study within the last 30 days

发起方

niversity of the Saarland